Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APP | P05067 | 3/20 | 0.35 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.34 |
| ▸ | KDR | P35968 | 4/20 | 0.33 |
| ▸ | NTRK1 | P04629 | 4/20 | 0.33 |
| ▸ | NTRK3 | Q16288 | 4/20 | 0.33 |
| ▸ | NTRK2 | Q16620 | 4/20 | 0.33 |
| ▸ | CHEK1 | O14757 | 3/20 | 0.33 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.33 |
| ▸ | IDH1 | O75874 | 1/20 | 0.31 |
| ▸ | BTK | Q06187 | 1/20 | 0.31 |
| ▸ | PDE10A | Q9Y233 | 2/20 | 0.31 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4149490 | 0.79 | KDR (0.48) | KDRNTRK1NTRK3NTRK2CHEK1 | |
| SCHEMBL4142195 | 0.78 | CHEK1 (0.46) | KDRCHEK1IDH1FGFR1 | |
| SCHEMBL13927832 | 0.77 | KDR (0.40) | TGFBR1KDR | |
| SCHEMBL4144766 | 0.74 | KDR (0.47) | KDRCHEK1FGFR1 | |
| SCHEMBL4149528 | 0.74 | CHEK1 (0.50) | KDRCHEK1GRM4FGFR1 | |
| SCHEMBL4141491 | 0.73 | CHEK1 (0.50) | KDRCHEK1GRM4 | |
| SCHEMBL4139812 | 0.72 | KDM4E (0.38) | KDRCHEK1GRM4FGFR1 | |
| SCHEMBL4145365 | 0.71 | TTK (0.45) | KDRCHEK1 | |
| SCHEMBL4137397 | 0.71 | KDR (0.37) | KDRCHEK1GRM4 | |
| SCHEMBL9000609 | 0.70 | TGFBR1 (0.44) | APPTGFBR1GRM4IDH1PDE10A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090054397-A1 | PYRAZOLE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE COMPOUND | OHI NORIHITO | 2009-02-26 | — | — | US | disclosed |
| US-20050208582-A1 | Pyrazole compounds and pharmaceutical compositions comprising the compound | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2005-09-22 | — | — | US | disclosed |
| EP-1510516-A1 | PYRAZOLE COMPOUND AND MEDICINAL COMPOSITION CONTAINING THE SAME | Eisai Co., Ltd. (JP) | 2005-03-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090054397-A1 | PYRAZOLE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE COMPOUND | CNKSR1, NR3C2, CSNK2B | APP 4160/4885TGFBR1 994/4885KDR 932/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.